Combined Behavioral/Pharmacological Therapy for Insomnia
Recruitment status was Recruiting
This study will determine how sleeping pills can be combined with nondrug treatments to maximize the benefits of therapy for insomnia.
Sleep Initiation and Maintenance Disorders
Behavioral: Cognitive-Behavioral Therapy for Insomnia
Drug: zolpidem tartrate (Ambien)
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Combined Behavioral/Pharmacological Therapy for Insomnia|
|Study Start Date:||September 2001|
|Estimated Study Completion Date:||August 2006|
Long-term insomnia is a common and significant health problem. Two main treatments, pharmacotherapy and behavioral therapy, have been used to help people with insomnia. Because both treatments have advantages and disadvantages, a combination of these treatments may be a good way to treat insomnia.
During the first 2 weeks of the study, participants keep a sleep log, wear an actigraph (a device that resembles a wristwatch and records activity to help determine when participants are asleep or awake), and complete questionnaires.
Participants are then randomly assigned to receive 6 weeks of behavioral therapy plus zolpidem tartrate (Ambien), behavioral therapy plus placebo, or behavioral therapy alone. During treatment, participants return to the clinic once a week to turn in their sleep logs, download their actigraph, and complete questionnaires.
After 6 weeks, participants enter the post-treatment phase of the study, which lasts 2 weeks and is identical to the 2-week assessment at the beginning of the study.
After the post-treatment phase, participants enter the follow-up period and are contacted at 3 months, 6 months, and 1 year to complete another 2-week assessment with sleep logs, actigraphy, and questionnaires.
|United States, North Carolina|
|Duke Sleep Disorders Center||Recruiting|
|Durham, North Carolina, United States, 27710|
|Contact: William K Wohlgemuth, Ph.D. firstname.lastname@example.org|
|Contact: Victoria Herring 919-681-8392|
|Principal Investigator: William K Wohlgemuth, Ph.D.|
|Sub-Investigator: Andrew Krystal, M.D.|
|Sub-Investigator: Jack D Edinger, Ph.D.|